| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | ||
| 3 | Generic | GS 9132, ACH-806 | |
| 4 | Disease | Hepatitis C | |
| 5 | Mechanism | Protease Inhibitor ("which works through a novel mechanism of action involving HCV protease"), NS3/4A protease | |
| 6 | Development | phase 1 - healthy volunteers | |
| 7 | n | ~20 | |
| 8 | Results | Q2 2006 | |
| 9 | Competition | Enanta, ITMN, Medivir, SGP, VRTX, Idun | |
| 10 | Clinical Trials | p1b study to start in August |